Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants

NCT03363945 is registered in ClinicalTrials.gov with Medeor Therapeutics, Inc. as lead sponsor.

NCT NCT03363945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03363945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants
Lead sponsor
Medeor Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 15, 2018
Completion date
April 11, 2024
Enrollment
30 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant rejection